REFERENCES

• KesslerRC.BerglundP.DernierO.et alThe epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)JAMA.20032893095310512813115
   PubMed Web of Science ®Google Scholar
• PapakostasGI.FavaM.Does the probability of receiving placebo influence the likelihood of responding to placebo or clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDDNeuropsychopharmacology.200631(s1)s158
   Web of Science ®Google Scholar
• PetersenT.PapakostasGI.PosternakMA.et alEmpirical testing of two models for staging antidepressant treatment resistanceJ Clin Psychopharmacoi.200525336341
   PubMed Web of Science ®Google Scholar
• TrivediMH.RushAJ.WisniewskiSR.et alSTAR*D Study TeamEvaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practiceAm J Psychiatry.2006163284016390886
   PubMed Web of Science ®Google Scholar
• PapakostasGl.Augmentation strategies in the treatment of MDD: examining the evidence involving the use of atypical antipsychotic agentsCNSSpectr.200712(12 suppl 22)1012
   Google Scholar
• FavaM.BouffidesE.PavaJA.McCarthyMK.SteingardRJ.RosenbaumJF.Personality disorder comorbidity with major depression and response to fluoxetine treatmentPsychother Psychosom.1994621601677846259
   PubMed Web of Science ®Google Scholar
• FavaM.UebelackerLA.AlpertJE.NierenbergAA.PavaJA.RosenbaumJF.Major depressive subtypes and treatment responseBiol Psychiatry.1997425685769376453
   PubMed Web of Science ®Google Scholar
• HirschfeldRM.RussellJM.DelgadoPL.et alPredictors of response to acute treatment of chronic and double depression with sertraline or imipramineJ Clin Psychiatry.1998596696759921701
   PubMed Web of Science ®Google Scholar
• RussellJM.KoranLM.RushJ.et alEffect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depressionDepress Anxiety.200113182711233456
   PubMed Web of Science ®Google Scholar
• PetersenT.PapakostasGl.BottonariK.et alNEO-FFI factor scores as predictors of response to fluoxetine treatment in depressed outpatientsPsychiatry Res.200210991611850046
   PubMed Web of Science ®Google Scholar
• DemopulosC.FavaM.McLeanNE.AlpertJE.NierenbergAA.RosenbaumJF.Hypochondriacal concerns in depressed outpatientsPsychosomatMed.199658314320
   PubMed Web of Science ®Google Scholar
• FavaM.BlessE.OttoMW.PavaJA.RosenbaumJF.Dysfunctional attitudes in major depression. Changes with pharmacotherapyJ Nerv Ment Dis.199418245498277301
   PubMed Web of Science ®Google Scholar
• NewmanJR.EwingSE.McCollRD.et alTridimensional personality questionnaire and treatment response in major depressive disorder: a negative studyJ Affect Disord.20005724124710708838
   PubMed Web of Science ®Google Scholar
• losifescuDV.NierenbergAA.AlpertJE.et alThe impact of medical comorbidity on acute treatment in major depressive disorderAm J Psychiatry.20031602122212714638581
   PubMed Web of Science ®Google Scholar
• SonawallaS.PapakostasGl.PetersenT.et alElevated cholesterol levels in major depressive disorder associated with non-response to fluoxetine treatmentPsychosomatics.20024331031612189257
   PubMed Web of Science ®Google Scholar
• PapakostasGl.PetersenT.losifescuDV.et alObesity among outpatients with major depressive disorderInt J Neuropsychopharmacol.200471514720317
   PubMed Web of Science ®Google Scholar
• losifescuDV.Clementi-CravenN.FraguasR.et alCardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorderPsychosomatMed.200567703706
   PubMed Web of Science ®Google Scholar
• PapakostasGl.losifescuDV.RenshawPF.et alBrain MRI white matter hyperintensities, cardiovascular risk factors, and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II)Psychiatry Res: Neuroimag.2005140301307
   PubMed Web of Science ®Google Scholar
• FavaM.BorusJS.AlpertJE.NierenbergAA.RosenbaumJF.BottiglieriT.Folate, vitamin B12, and homocysteine in major depressive disorderAm J Psychiatry.19971544264289054796
   PubMed Web of Science ®Google Scholar
• PapakostasGl.PetersenT.LebowitzBD.etal.The relationship between serum folate, vitamin B12 and homocysteine levels in major depressive disorder and the timing of clinical improvement to fluoxetineInt J Neuropsychopharmacol.2005852352815877935
   PubMed Web of Science ®Google Scholar
• losifescuDV.RenshawPF.LyooIK.et alBrain MRI white matter hyperintensities, cardiovascular risk factors, and treatment outcome in major depressive disorderBr J Psychiatry.200618818018516449707
   PubMed Web of Science ®Google Scholar
• AlexopoulosGS.MurphyCF.Gunning-DixonFM.et alMicrostructural white matter abnormalities and remission of geriatric depressionAm J Psychiatry.200816523824418172016
   PubMed Web of Science ®Google Scholar
• FavaM.LabbateLA.AbrahamME.RosenbaumJF.Hypothyroidism and hyperthyroidism in major depression revisitedJ Clin Psychiatry.1995561861927737957
   PubMed Web of Science ®Google Scholar
• MischoulonD.BurgerJK.SpillmannMK.WorthingtonJJ.FavaM.AlpertJE.Anemia and macrocytosis in the prediction of serum folate and vitamin B12 status, and treatment outcome in major depressionJ Psychosomat Res.200049183187
   PubMed Web of Science ®Google Scholar
• PapakostasGl.PetersenT.PavaJ.et alHopelessness as a predictor of non-response to fluoxetine in major depressive disorderAnn Clin Psychiatry.2007195817453655
   PubMedGoogle Scholar
• AlexopoulosGS.KiossesDN.HeoM.MurphyCF.ShanmughamB.Gunning-DixonFExecutive dysfunction and the course of geriatric depressionBiol Psychiatry.20055820421016018984
   PubMed Web of Science ®Google Scholar
• BurnsRA.LockT.EdwardsDR.et alPredictors of response to aminespecific antidepressantsJ Affect Disord.199535971068749837
   PubMed Web of Science ®Google Scholar
• DenningerJW.PapakostasGl.MahalY.et alSomatic symptoms in outpatients with major depressive disorder treated with fluoxetinePsychosomatics.20064734835216844895
   PubMed Web of Science ®Google Scholar
• PapakostasGl.PetersenT.losifescuDV.AlpertJE.NierenbergAA.FavaM.Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorderJ Clin Psychiatry.2004554354615119918
   PubMedGoogle Scholar
• PapakostasGl.McGrathPJ.StewartJ.et alPsychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorderPsychiatry Res.200816111612018755514
   PubMed Web of Science ®Google Scholar
• NierenbergAA.McLeanNE.AlpertJE.WorthingtonJJ.RosenbaumJF.FavaM.Early nonresponse to fluoxetine as a predictor of poor 8-week outcomeAm J Psychiatry.1995152150015037573590
   PubMed Web of Science ®Google Scholar
• NierenbergAA.FarabaughAH.AlpertJE.et alTiming of onset of antidepressant response with fluoxetine treatmentAm J Psychiatry.20001571423142810964858
   PubMed Web of Science ®Google Scholar
• AlpertJE.MaddocksA.NierenbergAA.O'SullivanR.et alAttention deficit hyperactivity disorder in childhood among adults with major depressionPsychiatry Res.1996622132198804131
   PubMed Web of Science ®Google Scholar
• FavaM.HoogSL.JudgeRA.KoppJB.NilssonME.GonzalesJS.Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomniaJ Clin Psychopharmacoi.200222137147
   PubMed Web of Science ®Google Scholar
• SimonGE.HeiligensteinJH.GrothausL.KatonW.RevickiD.Should anxiety and insomnia influence antidepressant selection: a randomized comparison of fluoxetine and imipramineJ Clin Psychiatry.19985949559501885
   PubMed Web of Science ®Google Scholar
• KennedySH.AndersenHF.LamRW.Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysisJ Psychiatry Neurosci.200631122131 16575428
   PubMed Web of Science ®Google Scholar
• FeigerAD.FlamentMF.BoyerP.GillespieJA.Sertraline versus fluoxetine in the treatment of major depression: a combined analysis of five double-blind comparator studiesInt Clin Psychopharmacoi.200318203210
   PubMed Web of Science ®Google Scholar
• LenzeEJ.MulsantBH.DewMA.et alGood treatment outcomes in late-life depression with comorbid anxietyJ Affect Disord.20037724725414612224
   PubMed Web of Science ®Google Scholar
• SirA.D'SouzaRF.UguzS.et alRandomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptomsJ Clin Psychiatry.2005661312132016259546
   PubMed Web of Science ®Google Scholar
• TollefsonGD.HolmanSL.SaylerME.PotvinJH.Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious featuresJ Clin Psychiatry.19945550598077155
   PubMed Web of Science ®Google Scholar
• ClearyP.GuyW.Factor analysis of the Hamilton Depression ScaleDrugs Exp CliniRes.19771115120
   Google Scholar
• HamiltonM.A rating scale for depressionJ Neurol Neurosurg Psychiatry.196023566214399272
   PubMed Web of Science ®Google Scholar
• RushAJ.TrivediMH.CarmodyTJ.et alResponse in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertralineNeuropsychopharmacology,20012513113811377926
   PubMed Web of Science ®Google Scholar
• RushAJ.BateySR.DonahueRMJ.AscherJA.CarmodyTJ.MetzA.Does pretreatment anxiety predict response to either bupropion SR or sertraline?J Affect Disord.2001 64818711292522
   PubMed Web of Science ®Google Scholar
• FavaM.RushAJ.AlpertJE.et alDo Outpatients with anxious vs. nonanxious major depressive disorder have different treatment outcomes? A STAR*D ReportAm J Psychiatry.2008165342351 18172020
   PubMed Web of Science ®Google Scholar
• PatienceDA.McGuireRJ.ScottAI.FreemanCP.The Edinburgh Primary Care Depression Study: personality disorder and outcomeBr J Psychiatry.19951673243307496640
   PubMed Web of Science ®Google Scholar
• ReichJH.Effect of DSM-III personality disorders on outcome of tricyclic antidepressant-treated nonpsychotic outpatients with major or minor depressive disorderPsychiatry Res.1990321751812367602
   PubMed Web of Science ®Google Scholar
• FriedmanRAParidesMBaffRMoranMKocsisJHPredictors of response to desiprarnine in dysthymiaJ Clin Psychopharmacoi.199515280283
   PubMed Web of Science ®Google Scholar
• JoffeRT.ReganJJ.Personality and response to tricyclic antidepressants in depressed patientsJ Nerv Ment Dis.19891777457492592964
   PubMed Web of Science ®Google Scholar
• JoycePR.MulderRT.CloningerCR.Temperament predicts clomipramine and desiprarnine response in major depressionJ Affect Disord.19943035468151047
   PubMed Web of Science ®Google Scholar
• KocsisJH.MasonBJ.FrancesAJ.SweeneyJ.MannJJ.MarinD.Prediction of response of chronic depression to imipramineJ Affect Disord.1989172552602529294
   PubMed Web of Science ®Google Scholar
• Mynors-WallisL.GathD.Predictors of treatment outcome for major depression in primary carePsychol Med.1997277317369153693
   PubMed Web of Science ®Google Scholar
• PapakostasGl.PetersenT.FarabaughA.et alPsychiatric comorbidity among responders and nonresponders to nortriptyline in treatment-resistant major depressive disorderJ Clin Psychiatry.2003641357136114658951
   PubMed Web of Science ®Google Scholar
• SheaMT.PilkonisPA.BeckhamE.et alPersonality disorders and treatment outcome in the NIMH Treatment of Depression Collaborative Research ProgramAm J Psychiatry.19901477117182343912
   PubMed Web of Science ®Google Scholar
• ZuckermanDM.PrusoffBA.WeissmanMM.PadianNS.Personality as a predictor of psychotherapy and pharmacotherapy outcome for depressed outpatientsJ Consult Clin Psychol.1980487307357440829
   PubMed Web of Science ®Google Scholar
• PeselowED.FieveRR.DiFigliaC.Personality traits and response to desiprarnineJ Affect Disord.1992242092161578076
   PubMed Web of Science ®Google Scholar
• SatoT.HiranoS.NaritaT.etal.Temperament and character inventory dimensions as a predictor of response to antidepressant treatment in major depressionJ Affect Disord.19995615316110701472
   PubMed Web of Science ®Google Scholar
• PapakostasGl.PetersenT.PavaJ.et alHopelessness and suicide in treatment-resistant depression: prevalence and impact on treatment outcomeJ Nerv Ment Dis.200319144444912891091
   PubMed Web of Science ®Google Scholar
• PapakostasGl.PetersenT.DenningerJ.et alSomatic symptoms in treatment-resistant depressionPsychiatry Res.2003118394512759160
   PubMed Web of Science ®Google Scholar
• PapakostasGl.PetersenT.SonawallaS.et alSerum cholesterol in treatment-resistant depressionNeuropsychobiology.20034714615112759558
   PubMed Web of Science ®Google Scholar
• PapakostasGl.PetersenT.losifescuDV.et alAxis III co-morbidity in treatment-resistant depressionPsychiatry Res.200311818318812798983
   PubMed Web of Science ®Google Scholar
• FlintAJ.RifatSL.Anxious depression in elderly patients. Response to antidepressant treatmentAm J Geriatr Psychiatry,199751071159106374
   PubMed Web of Science ®Google Scholar
• GrunhausL.RabinD.GredenJF.Simultaneous panic and depressive disorder: response to antidepressant treatmentsJ Clin Psychiatry.198647473941058
   PubMed Web of Science ®Google Scholar
• GrunhausL.HarelY.KruglerT.PandeAC.HaskettRF.Major depressive disorder and panic disorder. Effects of comorbidity on treatment outcome with antidepressant medicationsClin Neuropharmacol.1988114544613219677
   PubMed Web of Science ®Google Scholar
• AngstJ.ScheideggerP.StablM.Efficacy of moclobemide in different patient groups. Results of newsubscales of the Hamilton Depression Rating ScaleClin Neuropharmacol.199316 (suppl)2S55S628313398
   PubMed Web of Science ®Google Scholar
• Delini-StulaA.MikkelsenH.AngstJ.Therapeutic efficacy of antidepressants in agitated anxious depression - a meta-analysis of moclobemide studiesJ Affect Disord.19953521308557884
   PubMed Web of Science ®Google Scholar
• LiebowitzMR.QuitkinFM.StewartJW.et alAntidepressant specificity in atypical depressionArch Gen Psychiatry.1988451291373276282
   PubMed Web of Science ®Google Scholar
• QuitkinFM.StewartJW.McGrathPJ.et alPhenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI respondersAm J Psychiatry.19881453063113278631
   PubMed Web of Science ®Google Scholar
• QuitkinFM.McGrathPJ.StewartJW.et alAtypical depression, panic attacks, and response to imipramine and phenelzine. A replicationArch Gen Psychiatry.1990479359412222132
   PubMed Web of Science ®Google Scholar
• RobinsonDS.KayserA.CorcellaJ.LauxD.YinglingK.HowardD.Panic attacks in outpatients with depression: response to antidepressant treatmentPsychopharmacoi Bull.198521562567
   PubMedGoogle Scholar
• QuitkinFM.HarrisonW.StewartJW.et alResponse to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover designArch Gen Psychiatry.1991483193232009033
   PubMed Web of Science ®Google Scholar
• NelsonEC.CloningerCR.The tridimensional personality questionnaire as a predictor of response to nefazodone treatment of depressionJ Affect Disord.19953551578557887
   PubMed Web of Science ®Google Scholar
• NelsonECloninger.CRExploring the TPQ as a possible predictor of antidepressant response to nefazodone in a large multi-site studyJ Affect Disord.1997441972009241580
   PubMed Web of Science ®Google Scholar
• RushAJ.CarmodyTJ.HaightBR.RockettCB.ZisookS.Does pretreatment insomnia or anxiety predict acute response to bupropion SR?Ann Clin Psychiatry.2005171915941026
   PubMedGoogle Scholar
• PapakostasGl.StahlSM.KrishenA.et alEfficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression)J Clin Psychiatry.2008691287129218605812
   PubMed Web of Science ®Google Scholar
• DavidsonJR.Meoni P, Haudiquet V, Cantillon M, Hackett D. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptomsDepress Anxiety.20021641312203668
   PubMed Web of Science ®Google Scholar
• SilverstonePH.SalinasE.Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorderJ Clin Psychiatry.20016252352911488362
   PubMed Web of Science ®Google Scholar
• Thase MEEntsuah R.Cantillon MKornstein SG.Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactionsJ Womens Health.200514609616
   Web of Science ®Google Scholar
• KornsteinSG.WohlreichMM.MallinckrodtCH.WatkinJG.StewartDE.Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trialsJ Clin Psychiatry.20066776177016841626
   PubMed Web of Science ®Google Scholar
• MallinckrodtCH.WatkinJG.LiuC.WohlreichMM.RaskinJ.Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic featuresBioMed Central Psychiatry,20055115631624
   PubMedGoogle Scholar
• ThaseME.PritchettYL.OssannaMJ.SwindleRW.XuJ.DetkeMJ.Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorderJ Clin Psychopharmacoi.200727672676
   PubMed Web of Science ®Google Scholar
• HamBJ.LeeBC.PaikJW.et alAssociation between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean populationProgr Neuropsychopharmacol Biol Psychiatry.200731104107
   PubMed Web of Science ®Google Scholar
• SerrettiA.ZanardiR.RossiniD.CusinC.LilliR.SmeraldiE.Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activityMol Psychiatry.2001658659211526473
   PubMed Web of Science ®Google Scholar
• SerrettiA.ZanardiR.CusinC.RossiniD.LorenziC.SmeraldiE.Tryptophan hydroxylase gene associated with paroxetine antidepressant activityEurop Neuropsychopharmacology,200111375380
   PubMed Web of Science ®Google Scholar
• HongCJ.ChenTJ.YuYW.TsaiSJ.Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorderPharmacogenomics J.20066273316302021
   PubMed Web of Science ®Google Scholar
• KatoM.FukudaT.WakenoM.et alEffects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patientsNeuropsychobiology.20065318619516874005
   PubMed Web of Science ®Google Scholar
• YoshidaK.NaitoS.TakahashiH.et alMonoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorderProgr Neuropsychopharmacol Biol Psychiatry.20022612791283
   PubMed Web of Science ®Google Scholar
• AriasB.CatalanR.GastoC.GutierrezB.FananasL.5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up studyJ Clin Psychopharmacoi.200323563567
   PubMed Web of Science ®Google Scholar
• DurhamLK.WebbSM.MilosPM.ClaryCM.SeymourAB.The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorderPsychopharmacology.200417452552912955294
   PubMed Web of Science ®Google Scholar
• BozinaN.PelesAM.SagudM.BilusicH.JakovljevicM.Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorderWorld J Biol Psychiatry.2008919019717853254
   PubMed Web of Science ®Google Scholar
• KatoM.WakenoM.OkugawaG.FukudaT.AzumaJ.KinoshitaT.SerrettiA.No association of TPH1 218A/C polymorphism with treatment response and intolerance to SSRIs in Japanese patients with major depressionNeuropsychobiology.20075616717118332644
   PubMed Web of Science ®Google Scholar
• KronenbergS.ApterA.BrentD.Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disordersJ Child Adolescent Psychopharmacoi.200717741750
   PubMed Web of Science ®Google Scholar
• NgCH.EastealS.TanS.SchweitzerI.HoBK.AzizS.Serotonin transporter polymorphisms and clinical response to sertraline across ethnicitiesProgr Neuropsychopharmacol Biol Psychiatry.200630953957
   PubMed Web of Science ®Google Scholar
• RauschJL.HobbyHM.ShendarkarN.JohnsonME.LiJ.Fluvoxamine treatment of mixed anxiety and depression: evidence for serotonergically mediated anxiolysisClin Psychopharmacoi.200121139142
   PubMed Web of Science ®Google Scholar
• SmeraldiE.ZanardiR.BenedettiF.Di BellaD.PerezJ.CatalaneM.Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamineMol Psychiatry.199835085119857976
   PubMed Web of Science ®Google Scholar
• YuYW.TsaiSJ.ChenTJ.LinCH.HongCJ.Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disordersMol Psychiatry.200271115111912476327
   PubMed Web of Science ®Google Scholar
• ZanardiR.BenedettiF.Di BellaD.CatalanoM.SmeraldiE.Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter geneJ Clin Psychopharmacoi.200020105107
   PubMed Web of Science ®Google Scholar
• ZanardiR.SerrettiA.RossiniD.etal.Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depressionBiol Psychiatry.20015032333011543734
   PubMed Web of Science ®Google Scholar
• Dmitrzak-WeglarzM.Rajewska-RagerA.GattnerK.et alAssociation studies of 5HT2Â and 5HTTLPR polymorphisms and drug response in depression patientsEur Neuropsychopharmacol.200717(s4)S238
   Web of Science ®Google Scholar
• KimD.K.LimS.W.LeeS.et alSerotonin transporter gene polymorphism and antidepressant responseNeuroreport.20001121521910683861
   PubMed Web of Science ®Google Scholar
• KraftJB.SlagerSL.McGrathPJ.HamiltonSP.Sequence analysis of the serotonin transporter and associations with antidepressant responseBiol Psychiatry.20055837438115993855
   PubMed Web of Science ®Google Scholar
• MinovC.BaghaiTC.SchuleC.et alSerotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depressionNeurosci Lett.200130311912211311507
   PubMed Web of Science ®Google Scholar
• YoshidaK.ItoK.SatoK.et alInfluence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patientsProgr Neuropsychopharmacol Biol Psychiatry.200226383386
   PubMed Web of Science ®Google Scholar
• SerrettiA.CusinC.RauschJL.BondyB.SmeraldiE.Pooling pharmacogenetic studies on the serotonin transporter: a mega-analysisPsychiatry Res.2006145616517069894
   PubMed Web of Science ®Google Scholar
• SerrettiA.KatoM.De RonchiD.KinoshitaT.Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patientsMol Psychiatry.20071224725717146470
   PubMed Web of Science ®Google Scholar
• SmltsKM.SmitsLJ.SchoutenJS.StelrnaFF.NelemansP.PrinsMH.Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic reviewMol Psychiatry,2004943344115037864
   PubMed Web of Science ®Google Scholar
• KraftJB.PetersEJ.SlagerSL.et alAnalysis of association between the serotonin transporter and antidepressant response in a large clinical sampleBiol Psychiatry.20076173474217123473
   PubMed Web of Science ®Google Scholar
• HuXZ.RushAJ.CharneyD.et alAssociation between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depressionArch Gen Psychiatry.20076478379217606812
   PubMed Web of Science ®Google Scholar
• ChoiMJ.KangRH.HamBJ.JeongHY.LeeMS.Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopramNeuropsychobiology.20055215516216127283
   PubMed Web of Science ®Google Scholar
• SatoK.YoshidaK.TakahashiH.et alAssociation between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorderNeuropsychobiology.20024613614012422060
   PubMed Web of Science ®Google Scholar
• McMahonFJ.BuervenichS.CharneyD.et alVariation in the gene encoding the serotonin 2Â receptor is associated with outcome of antidepressant treatmentAm J Hum Genet.20067880481416642436
   PubMed Web of Science ®Google Scholar
• PerlisRH.MoorjaniP.EagernessJ.et alPharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D StudyNeuropsychopharmacol.20083328102819
   PubMed Web of Science ®Google Scholar
• PaddockS.LajeG.CharneyD.et alAssociation of GRIK4 with Outcome of Antidepressant Treatment in the STAR*D CohortAm J Psychiatry.20071641181118817671280
   PubMed Web of Science ®Google Scholar
• LekmanM.LajeG.CharneyD.et alThe FKBP5-gene in depression and treatment response-an association study in the sequenced treatment alternatives to relieve depression (STAR*D) cohortBiol Psychiatry.2008631103111018191112
   PubMed Web of Science ®Google Scholar
• TsapakisEM.CheckleyS.KerwinRW.AitchisonKJ.Association between the serotonin transporter linked polymorphic region gene (5HTTLPR) and response to tricyclic antidepressants (TCAs)Eur Neuropsychopharmacol.200313S250
   Web of Science ®Google Scholar
• ChoiTK.KooMS.LeeSH.SeokJH.KirnSJ.Serotonin transporter gene polymorphism associated with venlafaxine treatment responseEur Neuropsychopharmacol.200717(s4)S228
   Web of Science ®Google Scholar
• KangRH.WongML.ChoiMJ.PaikJW.LeeMS.Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorderProgr Neuropsychopharmacol Biol Psychiatry.20073113171321
   PubMed Web of Science ®Google Scholar
• MullerDJ.SchulzeTG.MacciardiF.et alMoclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase A promoterPharmacopsychiatry,20023515715812163988
   PubMed Web of Science ®Google Scholar
• JoycePR.MulderRT.LutySE.et alAge-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptylineInt J Neuropsychopharmacol.2003633934614604448
   PubMed Web of Science ®Google Scholar
• SzegediA.RujescuD.TadicA.et alThe catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depressionPharmacogenomics J.20055495315520843
   PubMed Web of Science ®Google Scholar
• MaybergHS.SilvaJA.BrannanSK.et alThe functional neuroanatomy of the placebo effectAm J Psychiatry.200215972873711986125
   PubMed Web of Science ®Google Scholar
• MaybergHS.BrannanSK.TekellJL.etal.Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical responseBiol Psychiatry.20004883084311063978
   PubMed Web of Science ®Google Scholar
• losifescuDV.BobNR.NierenbergAA.JensenJE.FavaM.RenshawPFBrain bioenergetics and response to triiodothyronine augmentation in major depressive disorderBiol Psychiatry.2008631127113418206856
   PubMed Web of Science ®Google Scholar
• LittleJT.KetterTA.KimbrellTA.et alBupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depressionBiol Psychiatry.20055722022815691522
   PubMed Web of Science ®Google Scholar
• HunterAM.CookIA.LeuchterAF.The promise of the quantitative electroencephalogram as a predictor of antidepressant treatment outcomes in major depressive disorderPsychiatr Clin N Am.200730105124
   PubMed Web of Science ®Google Scholar
• LeuchterAF.CookIA.LufkinRB.et alCordance: a new method for assessment of cerebral perfusion and metabolism using quantitative electroencephalographyNeurolmage.19941208219
   PubMedGoogle Scholar
• BaresM.BrunovskyM.KopecekM.et alChanges in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: a pilot studyJ Psych Res.200741319325
   Google Scholar
• CookIA.LeuchterAF.MorganM.et alEarly changes in prefrontal activity characterize clinical responders to antidepressantsNeuropsychopharmacol.200227120131
   PubMed Web of Science ®Google Scholar
• CookIA.LeuchterAF.MorganML.StubbemanW.SlegmanB.AbramsM.Changes in prefrontal activity characterize clinical response in SSRI nonresponders: a pilot studyJ Psych Res.200539461466
   Google Scholar
• LeuchterAF.CookIA.WitteEA.MorganM.AbramsM.Changes in brain function of depressed subjects during treatment with placeboAm J Psychiatry.200215912212911772700
   PubMed Web of Science ®Google Scholar
• HunterAM.LeuchterAF.MorganML.CookIA.Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depressionAm J Psychiatry.20061631426143216877657
   PubMed Web of Science ®Google Scholar
• HegerlU.JuckelG.Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: a new hypothesisBiol Psychiatry.1993331731878383545
   PubMed Web of Science ®Google Scholar
• GalllnatJ.BottlenderR.JuckelG.et alThe loudness dependency of the auditory evoked N1/P2-component as a predictor of the acute SSRI response in depressionPsychopharmacology (Berl).200014840441110928314
   PubMed Web of Science ®Google Scholar
• LinkaT.MillierBW.BenderS.SartoryG.The intensity dependence of the auditory evoked N1 component as a predictor of response to Citalopram treatment in patients with major depressionNeurosci Lett.200436737537815337269
   PubMed Web of Science ®Google Scholar
• MulertC.JuckelG.AugustinH.HegerlU.Comparison between the analysis of the loudness dependency of the auditory N1/P2 component with LORETA and dipole source analysis in the prediction of treatment response to the selective serotonin reuptake inhibitor citalopram in major depressionClin Neurophysiol.20021131566157212350432
   PubMed Web of Science ®Google Scholar
• MulertC.JuckelG.BrunnmeierM.et alPrediction of treatment response in major depression: integration of conceptsJ Affect Disord.20079821522516996140
   PubMed Web of Science ®Google Scholar
• PaigeSR.FitzpatrickDF.KlineJP.BaloghSE.HendricksSE.Event-related potential amplitude/intensity slopes predict response to antidepressantsNeuropsychobiology.1994301972017862269
   PubMed Web of Science ®Google Scholar
• JuckelG.PogarellO.AugustinH.et alDifferential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorderJ Clin Psychiatry.2007681206121217854244
   PubMed Web of Science ®Google Scholar
• BruderGE.StewartJW.VoglmaierMM.et alCerebral laterality and depression: relations of perceptual asymmetry to outcome of treatment with tricyclic antidepressantsNeuropsychopharmacology.199031102306330
   PubMed Web of Science ®Google Scholar
• BruderGE.OttoMW.McGrathPJ.et alDichotic listening before and after fluoxetine treatment for major depression: relations of laterality to therapeutic responseNeuropsychopharmacology,1996151711798840353
   PubMed Web of Science ®Google Scholar
• BruderGE.StewartJW.McGrathPJ.DeliyannidesD.QuitkinFM.Dichotic listening tests of functional brain asymmetry predict response to fluoxetine in depressed women and men.Neuropsychopharmacology,2004291752176115238992
   PubMed Web of Science ®Google Scholar
• BraderGE.StewartJW.SchallerJD.McGrathPJ.Predicting therapeutic response to secondary treatment with bupropion: Dichotic listening tests of functional brain asymmetry.Psychiatry Res.200715313714317651813
   PubMed Web of Science ®Google Scholar